Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Hims & Hers vs TeleClinic

By GLP-1 ScorecardUpdated

Hims & Hers
Site position #56

Higher grade

TeleClinic
Site position #357

Lower grade

Score comparison

Hims & Hers has the higher recorded score — 75.6/100 to 60.8/100.

Hims & Hers grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Mass-market app-first program with nationwide reach and consumer-grade polish.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueHims & Hers +38
82
44
Dose & formulationHims & Hers +14
78
64
Clinical oversightTeleClinic +25
55
80
Labs & monitoringHims & Hers +28
80
52
FulfillmentTeleClinic +13
84
97
Contract termsHims & Hers +60
80
20
Hims & Hers · top barTeleClinic · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricHims & HersTeleClinic
WeighScore75.6/10060.8/100
GradeCC
Site position#56#357
Semaglutide$199/mo$199/mo (compounded)
TirzepatideNot disclosed$299/mo (compounded)
CoverageAll 50 states47 states
Brand-name accessNot confirmedNot confirmed
Oral / sublingualNot confirmedNot confirmed
Hims & Hers

Site position #56 · C

FDAWarning letter issued to Hims & Hers Health, Inc. dba Hims in September 2025. See the FDA warning-letter database.

Strengths

  • Nationwide
  • Polished app
  • Strong brand trust

What to consider

  • Tirzepatide pricing inconsistently disclosed
  • Industry-wide compounding scrutiny
TeleClinic

Site position #357 · C

Strengths

  • Names its pharmacy partner — Rush Pharmacy, a licensed 503A compounder — which many compounded-GLP-1 telehealths won't disclose
  • LegitScript certified with flat, published monthly pricing, free shipping, and no insurance required
  • Broad access: 47 states with US-licensed physicians and transparent cash-pay pricing

What to consider

  • Compounded semaglutide and tirzepatide only — no brand-name GLP-1 (Wegovy or Zepbound) option
  • Headline $139/$219 rates are first-quarter intro prices billed quarterly; ongoing month-to-month is $199/$299
  • Not available in California, South Carolina, or New Jersey

Featured provider

CoreAge Rx

CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.

Commercial relationships affect this placement. The score comparison above is separate.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard